Physician profile
Daniel Robert Breazeale
NPI 1083686463
$562.13
in general payments reported to CMS, 2019-2025
17 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $51.63 · 2022: $33.86 · 2023: $72.64 · 2024: $58.01 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $178.74 | 2019-2025 | |
| Biogen, INC. | $55.71 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $39.49 | 2024-2025 | Endosee, Paragard T 380a |
| Pfizer INC. | $38.42 | 2023 | |
| Evofem Biosciences, INC. | $35.87 | 2025 | Phexxi, Solosec, Phexx |
| Duchesnay USA Incorporated | $35.64 | 2019 | |
| Vertical Pharmaceuticals, LLC | $30.04 | 2019 | |
| Sumitomo Pharma America, INC. | $26.82 | 2025 | Myfembree |
| Vertex Pharmaceuticals Incorporated | $23.12 | 2024 | |
| Novo Nordisk INC | $18.94 | 2023 | Wegovy |
| Hologic Sales and Service, LLC | $15.07 | 2024 | Acessa Provu System, Myosure Tissue Removal Device |
| Mylan Pharmaceuticals INC. | $14.43 | 2019 | |
| Millicent US INC | $13.57 | 2025 | Femlyv |
| Zyla Life Sciences, INC. | $13.22 | 2020 | |
| Abbvie INC. | $12.26 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $10.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Breazeale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.